Tyra biosciences announces preclinical proof-of-concept results with tyra-300 in hypochondroplasia (hch)

- in a preclinical hch model, tyra-300 demonstrated increases in long bone length and binding against the hch altered protein -  -tyra remains on track to submit ach investigational new drug application (ind) in 2h24- carlsbad, calif. , july 2, 2024 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, today announced preclinical proof-of-concept results with tyra-300, an investigational oral fgfr3 selective inhibitor, in hypochondroplasia (hch).
TYRA Ratings Summary
TYRA Quant Ranking